RALGDS and cancer: The third effector pathway downstream of Ras, the RalGDS-Ral pathway, has not yet been successfully targeted therapeutically despite growing evidence implicating this pathway as a critical mediator of survival in several Ras-mutant cancers, including pancreatic, colorectal, bladder, and melanoma (19).